Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,108.40
(
-0.41%
)
US TECH 100
26,206.40
(
0.01%
)
Dow Jones
49,310.32
(
-0.36%
)
Brent Oil
100.36
(
-0.83%
)
Bitcoin
77,851.02
(
-0.55%
)
News Focus
News Focus
Post# of 257442
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122884
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mcbio post# 128590

Monday, 10/17/2011 1:40:32 AM

Monday, October 17, 2011 1:40:32 AM

Post# of 257442

I just wonder if maybe Roche has an eye on ACHN as well, if they're on the HCV prowl. They could pair ANA598 with a potentially better PI (ACH-1625 or ACH-2684) and/or one of ACHN's NS5A inhibitors down the road with an acquisition of ACHN.

If that were the plan, wouldn’t it make more sense for Roche to move on ACHN first and then go after ANDS later?

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today